Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


10.01.2022

2 Anticancer Res
6 BJU Int
2 BMC Urol
1 Cancer
6 Cancer Lett
1 Eur J Radiol
2 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 Int J Urol
2 J Clin Oncol
13 J Nucl Med
7 J Urol
1 JAMA
4 Lancet Oncol
1 Oncogene
1 Oncol Rep
2 PLoS One
3 Prostate
2 Urology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Anticancer Res

  1. LEHTONEN M, Sormunen J, Hjalm-Eriksson M, Thellenberg-Karlsson C, et al
    Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
    Anticancer Res. 2022;42:87-92.
    PubMed         Abstract available

  2. IACOVELLI R, Ciccarese C, Caffo O, De Giorgi U, et al
    The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.
    Anticancer Res. 2022;42:165-172.
    PubMed         Abstract available


    BJU Int


  3. Acute Urinary Retention and Cancer; Is It All About the Prostate?
    BJU Int. 2021;128:660.
    PubMed        

  4. PALUDO AO, Knijnik PG, Silva Neto B, Berger M, et al
    Initial experience with first postoperative day Foley catheter removal after robot-assisted radical prostatectomy.
    BJU Int. 2021;128:555-557.
    PubMed        

  5. LENFANT L, Corrigan D, Beksac AT, Schwen Z, et al
    Learning curve analysis of single-port robot-assisted extraperitoneal prostatectomy using the cumulative sum (CUSUM) method.
    BJU Int. 2021;128:688-691.
    PubMed        

  6. ZHANG Z, Lampotang S, Yu Y, Acar YA, et al
    Attitude is everything: keep probe pitch neutral during side-fire prostate biopsy. A simulator study.
    BJU Int. 2021;128:615-624.
    PubMed         Abstract available

  7. SANDAHL M, Pedersen BG, Ulhoi BP, Borre M, et al
    Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
    BJU Int. 2021;128:702-712.
    PubMed         Abstract available

  8. TULLY KH, Schulmeyer M, Hanske J, Reike MJ, et al
    Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
    BJU Int. 2021;128:598-606.
    PubMed         Abstract available


    BMC Urol

  9. LIN D, Liu T, Chen L, Chen Z, et al
    Body mass index in relation to prostate-specific antigen-related parameters.
    BMC Urol. 2021;21:130.
    PubMed         Abstract available

  10. YOO JW, Koo KC, Chung BH, Lee KS, et al
    Efficacy of additional periprostatic apex nerve block on pain in each of 12 transrectal prostate core biopsies: a retrospective study.
    BMC Urol. 2021;21:132.
    PubMed         Abstract available


    Cancer

  11. WITTMANN D, Mehta A, Bober SL, Zhu Z, et al
    TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results.
    Cancer. 2022 Jan 5. doi: 10.1002/cncr.34076.
    PubMed         Abstract available


    Cancer Lett

  12. HERNANDEZ I, Cohen M
    Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
    Cancer Lett. 2022;524:1-14.
    PubMed         Abstract available

  13. CHALLASIVAKANAKA S, Vickman RE, Kakarla M, Hayward SW, et al
    Fibroblast heterogeneity in prostate carcinogenesis.
    Cancer Lett. 2022;525:76-83.
    PubMed         Abstract available

  14. CROWLEY L, Shen MM
    Heterogeneity and complexity of the prostate epithelium: New findings from single-cell RNA sequencing studies.
    Cancer Lett. 2022;525:108-114.
    PubMed         Abstract available

  15. BAEK DS, Kim YJ, Vergara S, Conard A, et al
    A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
    Cancer Lett. 2022;525:97-107.
    PubMed         Abstract available

  16. CHAKRABORTY S, Utter MB, Frias MA, Foster DA, et al
    Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.
    Cancer Lett. 2021;522:164-170.
    PubMed         Abstract available

  17. BERNASOCCHI T, Theurillat JP
    SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
    Cancer Lett. 2021;529:11-18.
    PubMed         Abstract available


    Eur J Radiol

  18. HAGEN F, Norz V, Thaiss WM, Mair A, et al
    Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience.
    Eur J Radiol. 2021;146:110059.
    PubMed         Abstract available


    Eur Urol

  19. CLEMENTS MB, Vertosick EA, Guerrios-Rivera L, De Hoedt AM, et al
    Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort.
    Eur Urol. 2021 Dec 31. pii: S0302-2838(21)02222.
    PubMed         Abstract available

  20. WILLEMSE PM, Davis NF, Grivas N, Zattoni F, et al
    Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
    Eur Urol. 2021 Dec 31. pii: S0302-2838(21)02215.
    PubMed         Abstract available


    Int J Cancer

  21. FAN Z, Ma J, Pan X, Zhao L, et al
    Crosstalk of FGFR1 signaling and choline metabolism promotes cell proliferation and survival in prostate cancer cells.
    Int J Cancer. 2022 Jan 5. doi: 10.1002/ijc.33922.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  22. RAMAN S, Keyes M, Oh J, Rousseau E, et al
    Patterns of prostate cancer recurrence after brachytherapy determined by PSMA PET/CT imaging.
    Int J Radiat Oncol Biol Phys. 2022 Jan 2. pii: S0360-3016(21)03437.
    PubMed         Abstract available


    Int J Urol

  23. HASEGAWA M, Yamada K, Shigeta K, Yuzuriha S, et al
    How long should urologists observe patients with prostate cancer after radical prostatectomy? Weibull analysis.
    Int J Urol. 2022 Jan 4. doi: 10.1111/iju.14774.
    PubMed         Abstract available


    J Clin Oncol

  24. DZIMITROWICZ HE, Armstrong AJ
    Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.
    J Clin Oncol. 2022 Jan 6:JCO2102504. doi: 10.1200/JCO.21.02504.
    PubMed        

  25. MORGANS AK, Beltran H
    Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer.
    J Clin Oncol. 2022 Jan 6:JCO2102530. doi: 10.1200/JCO.21.02530.
    PubMed         Abstract available


    J Nucl Med

  26. MEIJER D, Donswijk ML, Bodar YJL, van Leeuwen PJ, et al
    Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging.
    J Nucl Med. 2020 Nov 6. pii: jnumed.120.252528. doi: 10.2967/jnumed.120.252528.
    PubMed         Abstract available

  27. URBAN S, Meyer C, Dahlbom M, Farkas I, et al
    Radiation Dosimetry of (99m)Tc-PSMA I&S: A Single-Center Prospective Study.
    J Nucl Med. 2021;62:1075-1081.
    PubMed         Abstract available

  28. FERNANDEZ R, Eppard E, Lehnert W, Jimenez-Franco LD, et al
    Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases.
    J Nucl Med. 2021;62:1126-1132.
    PubMed         Abstract available

  29. YUSUFI N, Wurzer A, Herz M, D'Alessandria C, et al
    Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using (19)F/(177)Lu-rhPSMA-7.3 and (177)Lu-PSMA I&T.
    J Nucl Med. 2021;62:1106-1111.
    PubMed         Abstract available

  30. EDER AC, Schafer M, Schmidt J, Bauder-Wust U, et al
    Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules.
    J Nucl Med. 2021;62:1461-1467.
    PubMed         Abstract available

  31. NOTNI J
    PSMA-Targeted Therapeutics: A Tale About Law and Economics.
    J Nucl Med. 2021;62:1482.
    PubMed        

  32. LANGBEIN T, Wang H, Rauscher I, Kronke M, et al
    Utility of (18)F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
    J Nucl Med. 2022 Jan 6. pii: jnumed.121.263440. doi: 10.2967/jnumed.121.263440.
    PubMed         Abstract available

  33. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:69-75.
    PubMed         Abstract available

  34. CALAIS J, Czernin J
    PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
    J Nucl Med. 2021;62:1489-1491.
    PubMed        

  35. SRINIVAS S, Iagaru A
    To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.
    J Nucl Med. 2021;62:1487-1488.
    PubMed        

  36. BRENNER W, Strobel J, Prasad V
    PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
    J Nucl Med. 2021;62:1242-1243.
    PubMed        

  37. CALAIS J, Czernin J, Thin P, Gartmann J, et al
    Safety of PSMA-Targeted Molecular Radioligand Therapy with (177)Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
    J Nucl Med. 2021;62:1447-1456.
    PubMed         Abstract available

  38. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021;62:1025-1026.
    PubMed        


    J Urol

  39. GROSSO AA, Di Maida F, Mari A, Minervini A, et al
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Health Care System: A Population-Based Analysis. Letter.
    J Urol. 2022 Jan 4:101097JU0000000000002418. doi: 10.1097/JU.0000000000002418.
    PubMed        

  40. TANAKA T, Kawashima A, Rangel LJ, Schulte PJ, et al
    Long Term Risk of Clinical Progression Utilizing MRI Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence Following Radical Prostatectomy.
    J Urol. 2022 Jan 4:101097JU0000000000002421. doi: 10.1097/JU.0000000000002421.
    PubMed         Abstract available

  41. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2022 Jan 7:101097JU0000000000002413. doi: 10.1097/JU.0000000000002413.
    PubMed        

  42. NAYAK JG
    The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis. Reply.
    J Urol. 2022 Jan 4:101097JU0000000000002419. doi: 10.1097/JU.0000000000002419.
    PubMed        

  43. CHAPPIDI MR, Bell A, Cowan JE, Greenberg SA, et al
    The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
    J Urol. 2022 Jan 4:101097JU0000000000002420. doi: 10.1097/JU.0000000000002420.
    PubMed         Abstract available

  44. PINTHUS JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, et al
    Low Serum Testosterone in Men With Newly Diagnosed Androgen-Deprivation Therapy-Naive Prostate Cancer and Its Relationship to Cardiovascular Risk Factors-A Radical PC Substudy.
    J Urol. 2022 Jan 3:101097JU0000000000002384. doi: 10.1097/JU.0000000000002384.
    PubMed         Abstract available

  45. LUCKENBAUGH AN, Wallis CJD, Huang LC, Wittmann D, et al
    Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes.
    J Urol. 2022 Jan 3:101097JU0000000000002370. doi: 10.1097/JU.0000000000002370.
    PubMed         Abstract available


    JAMA

  46. SLOMSKI A
    Some Men With Localized Prostate Cancer Regret Surgery.
    JAMA. 2022;327:26.
    PubMed        


    Lancet Oncol

  47. SAAD F, De Porre P, Brookman-May S, Li J, et al
    Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply.
    Lancet Oncol. 2022;23:e5-e6.
    PubMed        

  48. GOMEZ-ITURRIAGA A, Keyes M, Martin J, Spratt DE, et al
    Should brachytherapy be added to external beam radiotherapy for prostate cancer?
    Lancet Oncol. 2022;23:23-25.
    PubMed        

  49. GILBOA S, Bomze D, Markel G, Meirson T, et al
    Radiographic progression-free survival in the ACIS trial for prostate cancer.
    Lancet Oncol. 2022;23:e3.
    PubMed        

  50. TANNOCK IF, Booth CM, Gyawali B, Joshua AM, et al
    Radiographic progression-free survival in the ACIS trial for prostate cancer.
    Lancet Oncol. 2022;23:e4.
    PubMed        


    Oncogene

  51. HAN W, Liu M, Han D, Li M, et al
    RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.
    Oncogene. 2022 Jan 3. pii: 10.1038/s41388-021-02135.
    PubMed         Abstract available


    Oncol Rep

  52. GU P, Zhang M, Zhu J, He X, et al
    Suppression of CDCA3 inhibits prostate cancer progression via NFkappaB/cyclin D1 signaling inactivation and p21 accumulation.
    Oncol Rep. 2022;47.
    PubMed         Abstract available


    PLoS One

  53. KIM SI, Szeto AH, Morgan KP, Brower B, et al
    Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    PLoS One. 2021;16:e0262326.
    PubMed         Abstract available

  54. KIM J, Cho S, Park Y, Lee J, et al
    Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer.
    PLoS One. 2021;16:e0262017.
    PubMed         Abstract available


    Prostate

  55. VLACHOSTERGIOS PJ, Niaz MJ, Thomas C, Christos PJ, et al
    Pilot study of the diagnostic utility of (89) Zr-df-IAB2M and (68) Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer.
    Prostate. 2022 Jan 5. doi: 10.1002/pros.24294.
    PubMed         Abstract available

  56. RASPIN K, O'Malley DE, Marthick JR, Donovan S, et al
    Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
    Prostate. 2022 Jan 7. doi: 10.1002/pros.24300.
    PubMed         Abstract available

  57. SNIPAITIENE K, Bakavicius A, Lazutka JR, Ulys A, et al
    Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study.
    Prostate. 2021 Dec 30. doi: 10.1002/pros.24293.
    PubMed         Abstract available


    Urology

  58. NAKAI Y, Tanaka N, Asakawa I, Miyake M, et al
    Mirabegron reduces urinary frequency and improves overactive bladder symptoms at 3 months after (125)I-brachytherapy for prostate cancer: An open-labeled, randomized, non-placebo-controlled study.
    Urology. 2021 Dec 29. pii: S0090-4295(21)01183.
    PubMed         Abstract available

  59. ROEBUCK E, Sha W, Lu C, Miller C, et al
    Racial and Socioeconomic Disparities in MRI-Fusion Biopsy Utilization to Assess for Prostate Cancer.
    Urology. 2022 Jan 4. pii: S0090-4295(21)01201.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: